NDC properties for NDC 9 0069-1318
NDC item 00069131801
NDC 9 | 0069-1318 |
---|---|
NDC 10 | 0069-1318-01 |
NDC Item | 00069131801 |
packaging | 2 mL in 1 VIAL, MULTI-DOSE |
BLA | BLA125545 |
FDA SPL set id | 792529 |
Labeler | Pfizer Laboratories Div Pfizer Inc |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | BLA |
Marketing effective time low | 2020-11-09 |
Marketing status | ACTIVE |
NDC item 00069131804
NDC 9 | 0069-1318 |
---|---|
NDC 10 | 0069-1318-04 |
NDC Item | 00069131804 |
packaging | 4 VIAL, MULTI-DOSE in 1 CARTON (0069-1318-04) / 2 mL in 1 VIAL, MULTI-DOSE (0069-1318-01) |
BLA | BLA125545 |
FDA SPL set id | 792529 |
Labeler | Pfizer Laboratories Div Pfizer Inc |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | BLA |
Marketing effective time low | 2020-11-09 |
Marketing status | ACTIVE |
NDC item 00069131810
NDC 9 | 0069-1318 |
---|---|
NDC 10 | 0069-1318-10 |
NDC Item | 00069131810 |
packaging | 10 VIAL, MULTI-DOSE in 1 CARTON (0069-1318-10) / 2 mL in 1 VIAL, MULTI-DOSE (0069-1318-01) |
BLA | BLA125545 |
FDA SPL set id | 792529 |
Labeler | Pfizer Laboratories Div Pfizer Inc |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | BLA |
Marketing effective time low | 2020-11-09 |
Marketing status | ACTIVE |
NDC item 59353022001
NDC 9 | 59353-220 |
---|---|
NDC 10 | 59353-220-01 |
NDC Item | 59353022001 |
packaging | 2 mL in 1 VIAL, MULTI-DOSE |
BLA | BLA125545 |
FDA SPL set id | 793734 |
Labeler | Vifor (International) Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | BLA |
Marketing effective time low | 2020-09-11 |
Marketing status | ACTIVE |
NDC item 59353022010
NDC 9 | 59353-220 |
---|---|
NDC 10 | 59353-220-10 |
NDC Item | 59353022010 |
packaging | 10 VIAL, MULTI-DOSE in 1 CARTON (59353-220-10) / 2 mL in 1 VIAL, MULTI-DOSE (59353-220-01) |
BLA | BLA125545 |
FDA SPL set id | 793734 |
Labeler | Vifor (International) Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | BLA |
Marketing effective time low | 2020-09-11 |
Marketing status | ACTIVE |